Infect Immun. 2006 Jan;74(1):390-3.

Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Wells J, Haidaris CG, Wright TW, Gigliotti F.

Source

University of Rochester School of Medicine and Dentistry, Department of Pediatrics, Box 690, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Abstract

Pneumocystis carinii is an opportunistic fungal pathogen that causes P. carinii pneumonia (PCP) in the immunocompromised host. We investigated the role of antibody Fc-mediated function in passive prophylaxis against the development of PCP in SCID mice. By comparison of anti-mouse P. carinii immunoglobulin G1 monoclonal antibody (MAb) 4F11(G1) and its F(ab')2 derivative in an intranasal immunoprophylaxis model, we determined that Fc-mediated function is required for maximum effect of this antibody. Comparison of efficacy of antibody prophylaxis in SCID mice depleted of complement to that in nondepleted mice demonstrated that complement fixation by MAb 4F11(G1) is also necessary for optimal effect of passively administered antibody, although residual protection was observed in complement-depleted SCID mice. The necessity of complement for optimal PCP prophylaxis by MAb 4F11(G1) suggests that complement may play a role in antibody-mediated protection against development of PCP.

PMID:: 16368994; [PubMed - indexed for MEDLINE]
PMCID: PMC1346672

Free PMC Article

Images from this publication.See all images (1) Free text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

Research Support, N.I.H., Extramural

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Pneumocystis Infections - MedlinePlus Health Information

Supplemental Content

Related citations

Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. [Infect Immun. 2002]
Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.
Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. Infect Immun. 2002 Mar; 70(3):1069-74.
Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. [Infect Immun. 2004]
Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.
Wells J, Gigliotti F, Simpson-Haidaris PJ, Haidaris CG. Infect Immun. 2004 Mar; 72(3):1548-56.
Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. [J Immunol. 2003]
Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody.
Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. J Immunol. 2003 Aug 1; 171(3):1423-30.
Review Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. [FEMS Immunol Med Microbiol. 1998]
Review Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis.
Séguy N, Polonelli L, Dei-Cas E, Cailliez JC. FEMS Immunol Med Microbiol. 1998 Sep; 22(1-2):145-9.
Review [Pathogenesis of pneumocystis carinii pneumonia]. [Pneumologie. 1999]
Review [Pathogenesis of pneumocystis carinii pneumonia].
Höffken G, Bäthge G, Kiderlen AF. Pneumologie. 1999 Nov; 53(11):530-8.

See reviews... See all...

Cited by 3 PubMed Central articles

A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. [Viral Immunol. 2010]
A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
Delaney KN, Phipps JP, Johnson JB, Mizel SB. Viral Immunol. 2010 Apr; 23(2):201-10.
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. [MAbs. 2010]
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
Moore GL, Chen H, Karki S, Lazar GA. MAbs. 2010 Mar-Apr; 2(2):181-9.
Review Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. [Infect Immun. 2007]
Review Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.
Casadevall A, Pirofski LA. Infect Immun. 2007 Nov; 75(11):5074-8. Epub 2007 Aug 20.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Complement and Fc function are required for optimal antibody prophylaxis against...
Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.
Infect Immun. 2006 Jan ;74(1):390-3.

PubMed
Microbial agents associated with waterborne diseases.
Microbial agents associated with waterborne diseases.
Crit Rev Microbiol. 2002 ;28(4):371-409.

PubMed
Control of human PIRH2 protein stability: involvement of TIP60 and the proteosom...
Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome.
J Biol Chem. 2004 Mar 19 ;279(12):11696-704. Epub 2003 Dec 29 .

PubMed
Is Mobitz type I atrioventricular block benign in adults?
Is Mobitz type I atrioventricular block benign in adults?
Heart. 2004 Feb ;90(2):169-74.

PubMed
Oligomerization of the yeast alpha-factor receptor: implications for dominant ne...
Oligomerization of the yeast alpha-factor receptor: implications for dominant negative effects of mutant receptors.
J Biol Chem. 2006 Jul 28 ;281(30):20698-714. Epub 2006 May 18 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: